摘要
目的:观察肝癌部分肝叶切除术后残肝断面植入5-氟尿嘧啶缓释剂(商品名:中人氟安)对肝癌转移复发的影响及其不良反应。方法:63例肝癌拟手术者随机分为两组:Ⅰ组(n=32)为普通化疗组,患者于肝癌肝叶部分切除术后行常规化疗;Ⅱ组(n=31)为缓释剂组,患者于肝癌肝叶部分切除术中残肝断面植入5-氟尿嘧啶缓释剂局部化疗。两组患者均随访一年,观察其不良反应、肿瘤复发率及患者死亡率。结果:术前两组患者肝功能无明显差异(P>0.05),术后Ⅱ组患者ALT、AST、TBL、PT、AFP水平均明显低于Ⅰ组(P<0.05);Ⅱ组患者术后复发转移率明显低于Ⅰ组(P<0.05);Ⅱ组患者的并发症发生率及死亡率均明显低于Ⅰ组患者(P<0.05)。结论:术中残肝断面植入5-氟尿嘧啶缓释剂疗效明显,能够减少肿瘤复发和转移,增加患者的耐受性与依从性,可有效防止肝癌术后转移复发,值得临床推广应用。
Objective： To study the effect and adverse effect of implanting sustained-release 5- fluorouracil during hepatolobectomy to oppose metastasis of liver cancer. Method： 63 patients diagnosed with liver cancer were divided into two groups ： group I （ n= 32 ）, ordinary chemotherapy group, patients with conventional chemotherapy after operation;group II （n = 31 ）, patients with sustained-release 5-fluorouracil during operation. Two groups were visited 1 year, observed the adverse effect, recurrence rate and death rate. Resuit： There＇s significant difference in liver function before operation（ P〉0.05） of two groups. ALT, AST, TBL, PT, AFP in group II were much lower than group I after operation （ P 〈 0.05 ） ; The recurrence and transferring rate of group II was much lower than group I （ P〈0.05 ） ; The incidence and mortality of group II were much lower than group I （ P〈0.05 ）. Conclusion： The treatment of sustained-release 5- fluorouracil during hepatolobectomy can effectively reduce the rate of transferring, recurrence and death of liver cancer patients, increase the patients＇ compliance and tolerance, it may be a new therapy for patients with liver cancer after hepatectomy.
出处
《河北医学》
CAS
2012年第6期777-780,共4页
Hebei Medicine
